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The overall prognosis of gastric cancer has gradually improved over the past de-
cades with growing awareness of potential carcinogens, surveillance programs and 
early diagnosis, as well as advances in surgical techniques and multimodality treat-
ments. Nevertheless, the outcome of advanced stage disease still remains poor 
with currently available treatments, and a worldwide consensus on the standard 
management thereof has not been established. To improve prognosis and quality 
of life in gastric cancer patients, both standardization and individualization of 
managements are imperative. Diagnostic tests and surgical procedures need to be 
further sophisticated and standardized based on more recent evidences from ongo-
ing and future randomized controlled trials, while comprehensive management 
should be individualized to each patient. Future challenges lie with how to opti-
mize personalized therapies by deciphering biological complexity of gastric cancer 
and incorporating molecular biomarkers in clinical practice to forecast prognosis 
and to guide targeted therapeutics in adjunct to current standards of care.
Key Words:   Stomach neoplasm, primary prevention, screening, gastrectomy, 
lymphadenectomy, biological marker, molecular therapeutics
INTRODUCTION
Gastric cancer remains a major health issue and a leading cause of cancer death 
worldwide, although the prevalence and mortality of the disease have gradually 
decreased.1,2 In Eastern Asia, including Korea and Japan, the incidence of gastric 
cancer is still high despite advances in treatment and subsequent improvement in 
prognosis. On the contrary, in the West, where the incidence has continuously de-
creased, the overall and stage-specific survival is worse than that in Eastern Asia.3 
Although the geographical differences in terms of incidence and prognosis have 
not yet been clearly elucidated, they are probably attributable to various factors in 
gastric carcinogenesis as well as in diagnostic and therapeutic strategies.
To conquer gastric cancer, primary prevention would be the best measure. Prac-
tically, however, a cure for gastric cancer can only be expected by both loco-re-
gional and systemic control of the disease with early diagnosis, and the quality of 
life (QoL) of individual patients, particularly in perioperative periods, has also be-
come an important component of comprehensive quality care. Nevertheless, man-
agement patterns vary worldwide and the survival gain from currently available 
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the well-known human model of gastric carcinogenesis 
proposed by Correa.13 Chronic inflammatory gastritis, asso-
ciated with H. pylori infection, is thought to form the initial 
lesion that induces progressive histopathological changes in 
gastric mucosa, towards chronic atrophic gastritis, intestinal 
metaplasia, dysplasia, and finally, intestinal-type adenocar-
cinoma. Recently, more attention has also been given to a 
role of stem cells in the gastric carcinogenesis initiated by 
H. pylori infection. Chronic damages to gastric mucosa al-
ter the maturation process of epithelial stem cells and thus 
recruit bone marrow-derived stem cells which potentiate 
the carcinogenic process.14 However, the relationship be-
tween H. pylori and gastric cancer still lacks evidence of a 
true causal relationship and its carcinogenic mechanism re-
mains to be further elucidated.
A recent meta-analysis of seven randomized trials15 
mostly conducted in Asia, where the infection rate of H. 
pylori is substantially high, demonstrated that eradication 
of H. pylori has the potential to prevent gastric cancer. Ac-
cordingly, updated Japanese guidelines for the manage-
ment of H. pylori and related diseases16 have finally indi-
cated that eradication of H. pylori is useful for the prevention 
of gastric cancer. Several antimicrobial regimens for H. py-
lori infection have been very successful, achieving eradi-
cation rates higher than 90%.17 It seems that earlier eradi-
cation thereof would accomplish a more significant 
decrease in gastric cancer risk.18 Nevertheless, identifying 
individuals with H. pylori infection is difficult because 
there is no specific symptom. Moreover, considering the 
high prevalence rates in epidemic regions like Eastern 
Asia, providing proper diagnostic tests and antibiotic treat-
ment to all infected individuals would be overwhelming.19 
Consequently, research into developing a vaccine against 
H. pylori in humans is ongoing, as application of a prophy-
lactic vaccine in clinical practice offers the best strategy to 
prevent H. pylori infection and to reduce the risk of devel-
oping gastric cancer.20
SECONDARY PREVENTION:  
EARLY DETECTION
To improve survival in gastric cancer patients, early detec-
tion and subsequent surveillance programs are essential,21 
and currently available screening tools include radiologic 
imaging and endoscopy with biopsy. Nationwide mass 
screening programs in Korea and Japan, where gastric can-
multimodality treatments seems to reach a plateau.
This article will review the current management of gas-
tric cancer in depth, discussing gastric carcinogenesis in re-
lation to the prevention of the disease, early detection with 
effective screening, and surgical treatment as the current 
standard of management, as well as a multidisciplinary ap-
proach for advanced disease. Furthermore, the current sta-
tus of molecular biomarkers and targeted therapy will be 
discussed as the future strategy for the tailored management 
of gastric cancer patients.
PRIMARY PREVENTION AND  
GASTRIC CARCINOGENESIS
According to the World Health Organization (WHO)᾽s Fight 
Against Cancer report,4 40% of all cancer deaths can be 
prevented. At the forefront of the health care system, prima-
ry care physicians play a critical role in cancer prevention 
by counseling individual patients on behaviors related to 
certain types of cancer.5
Tobacco smoking and the high consumption of salted 
and smoked foods are well known lifestyle and environ-
mental causes of gastric cancer.6 Overweight and obesity 
are also associated with increased risk of gastric cancer.7 
Although previous studies showed an inconsistent correla-
tion between gastric cancer and alcohol, a recent meta-anal-
ysis8 found a significant positive association between heavy 
alcohol intake and gastric cancer. On the other hand, there 
has been consistent evidence that vegetables and fruit are 
protective against gastric cancer.9 Following general cancer 
prevention guidelines, lifestyle modification, avoiding the 
aforementioned risk factors, seems to be the most effective 
and easiest way to reduce the incidence and mortality of 
gastric cancer.
Furthermore, Helicobacter pylori (H. pylori) has been clas-
sified as a class I carcinogen in humans by WHO since 
1994,10 based mainly on epidemiological evidence of its role 
in the pathogenesis of gastric carcinoma. Independent meta-
analyses have led to an overall consensus that H. pylori infec-
tion is associated with approximately a two-fold increased 
risk of developing gastric cancer,11 and this association has 
been reported to be stronger for patients younger than 30 
years of age.12 Beyond the epidemiologic evidence of H. py-
lori, several studies have also reported that the H. pylori in-
fection directly affects the carcinogenic mechanisms of gas-
tric cancer. For example, H. pylori plays a critical role in 
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antral G cells and its concentrations depend on the intragas-
tric acidity and number of G cells; therefore, measuring its 
serum level might predict the severity of atrophic gastritis.29 
However, as it only correlates with distal stomach status, se-
rum gastrin-17 cannot be used as a single serum marker for 
gastric cancer screening.23
In summary, a safe and effective screening strategy 
should be established to improve the prognosis of gastric 
cancer, in consideration of the incidence of the disease as 
well as the availability and cost-effectiveness of the screen-
ing method.
PRESENT STATUS OF GASTRIC  
CANCER MANAGEMENT
Radical gastrectomy with D2 lymphadenectomy
Radical (total or subtotal) gastrectomy is the gold standard 
of management of gastric cancer worldwide, as the com-
plete surgical removal of macroscopic and microscopic tu-
mors (R0 resection) confers the only chance for curing the 
disease. However, the extent of lymphadenectomy has been 
debated between the East and West. Radical gastrectomy 
with extended D2 lymphadenectomy is the accepted stan-
dard in Eastern Asia, whereas limited D1 resection with 
chemoradiotherapy is more frequently used in Western 
countries.30,31
The well-known European Phase III randomized controlled 
trials in the 1990s, carried out by the Medical Research Coun-
cil and Dutch Gastric Cancer Group, failed to show a survival 
benefit of D2 over D1 resections,32,33 with extremely high 
morbidity and hospital mortality in D2 group. However, it 
is not feasible to draw any definite conclusion of long-term 
survival benefit of D2 lymphadenectomy based on these tri-
als, because they had some critical problems which inevita-
bly lead to the substantially higher morbidity and mortality 
rates in D2 resections, compared to those reported by spe-
cialized high-volume centers in Korea, Japan, and Western 
countries as well. There was no standardized quality control 
of the participating surgeons and hospitals prior to these tri-
als and routine resection of the distal pancreas and spleen in 
total gastrectomy was defined as a part of D2 dissections in 
the trial protocol. To the contrary, splenectomy and distal 
pancreatectomy for removal of station 10 (parasplenic) and 
station 11 (parapancreatic) lymph nodes are no longer advo-
cated as a routine adjunctive procedure during D2 resec-
tions.34 Furthermore, it should be noted that the fifteen-year 
cer is the most common malignancy, has made it possible 
to detect the disease in earlier stages and to improve the 
overall survival rates of gastric cancer patients.22 However, 
most nations, except for Korea and Japan, have no national 
guidelines or recommendations for gastric cancer screen-
ing,23 as there are no screening tools applicable to low risk 
populations with respect to acceptable accuracy, minimal 
invasiveness, and low cost.24
The National Cancer Screening Program in Korea rec-
ommends that men and women older than 40 years of age 
receive gastric cancer screening every other year with ei-
ther direct upper-gastrointestinal series or endoscopy.25 In 
Japan, gastric cancer screening for all residents aged 40 
years and over is performed by annual photofluorography 
and further investigation by endoscopy on positive findings 
of photofluorography.26 In recent years, however, endosco-
py has been performed instead of photofluorography as the 
initial mass screening method in several cities in Japan, and 
a cohort analysis showed that endoscopic mass screening 
was superior in cost-effectiveness for screening gastric can-
cer patients.27 Indeed, endoscopy has been considered as the 
best diagnostic method of gastric cancer with advantages of 
direct visualization of gastric mucosa and collection of mu-
cosal specimens for histopathological evaluation. It is useful 
in detecting minute lesions in early gastric cancer (EGC) in 
particular, which is difficult to detect by upper-gastrointesti-
nal series alone. Accordingly, endoscopy would be the best 
screening tool in Korea and Japan, where the incidence of 
EGC is substantially high and endoscopy is readily per-
formed by experienced endoscopists at acceptable cost.
However, mass screening by endoscopy in other nations 
may not be the most practical approach, considering that 
endoscopy is an invasive procedure carrying potential com-
plications, and moreover, it is expensive in low-risk popula-
tions.23,24 Therefore, there is high demand for cost-effective 
and non-invasive tools for gastric cancer screening to detect 
premalignant lesions, and two serologic makers, serum 
pepsinogen and gastrin-17, have been reported by several 
studies. Human serum pepsinogens are proenzymes of pep-
sin, an endoproteinase of gastric juice. In a pooled meta-
analysis of Japanese studies assessing approximately 
300,000 people,28 the sensitivity and specificity of serum 
pepsinogen testing for gastric cancer screening were 77% 
and 73%, respectively. Subsequently, generalized cancer 
screening programs in Japan have accepted the measure-
ment of serum pepsinogen as a non-invasive serological 
screening test of gastric cancer. Gastrin-17 is secreted from 
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metastasis, and endoscopic submucosal dissection (ESD) 
has also recently become another treatment option with ad-
vances in endoscopic instrumentation and techniques.44 
Considering the benefits of ESD with minimal invasiveness 
of the procedure, it has the potential to extend its indication. 
Currently, however, a long-term oncological outcome has 
not been established despite its extensive use. Thus, while 
awaiting large scale oncologic safety data, surgical resection 
with appropriate lymph node dissection is the standard treat-
ment of EGC beyond conventional EMR criteria that is only 
limited to differentiated adenocarcinoma of less than 2 cm in 
diameter without ulceration and lymphovascular invasion.39
In recent years, minimally invasive surgery has been ad-
opted and widely used in Korea and Japan for EGC with 
low risk of lymph node metastasis, since laparoscopy-as-
sisted distal gastrectomy (LADG) with lymph node dissec-
tion was first reported in 1994 by Kitano, et al.45 However, 
it still remains an investigational treatment due to the lack 
of solid evidence in long-term oncologic outcomes from 
large-scale randomized controlled trials. Even though sev-
eral short-term benefits with the laparoscopic approach to 
gastric resection have been proposed, few have reported on 
the long-term QoL benefits of LADG over open distal gas-
trectomy (ODG). Yasuda, et al.46 conducted a retrospective 
comparison study of long-term QoL after LADG over 
ODG for EGC, and reported that QoL benefit of LADG in 
the early postoperative period was lost in the long-term fol-
low up of 99 months.
Currently, phase III multicenter trials are ongoing both in 
Korea (KLASS trial) and Japan (JCOG 0912) to compare 
the outcomes of LADG and ODG in the stage I gastric can-
cer, and the interim report of the KLASS trial demonstrated 
that LADG for early cancer is equivalent to ODG in terms 
of short-term outcomes, assessed by operative morbidity 
and mortality, but the long-term outcomes of final survival 
results are still awaited.47,48
The application of laparoscopic techniques in advanced 
gastric cancer (AGC) still remains controversial and needs 
more compelling evidence by well-designed prospective 
clinical trials prior to expanding its indications. The KLASS 
II trial has recently commenced in Korea and will provide 
answers on the technical feasibility and oncological safety 
of laparoscopic techniques in AGC, when the final results 
are reported.
Perioperative quality management
In the surgical management of cancer patients, QoL should 
follow-up of the Dutch trial35 recently reported that D2 
lymphadenectomy was associated with lower locoregional 
recurrence and gastric cancer related death rates than D1 
surgery after a median follow-up of 15 years. Also, the author 
suggested that spleen-preserving D2 resection is recommend-
ed as a standard management of resectable gastric cancer at 
high-volume specialized centers. Likewise, the interim report 
of a randomized controlled trial by the Italian Gastric Cancer 
Study Group showed no significant difference in postopera-
tive mortality and overall morbidity between D1 and pancre-
as-preserving D2 gastrectomy,36 suggesting that D2 resection 
is a safe option of radical gastrectomy in specialized centers 
of Western nations as well, although the final report of long-
term survival is still awaited.
Historically, a more extended lymph node dissection, such 
as D3 or para-aortic lymph node dissection (PAND), was 
once practiced in the hope of improving survival in patients 
with advanced diseases. PAND, however, is no longer per-
formed as a standard procedure, because the prospective 
randomized Japan Clinical Oncology Group (JCOG) study 
9501 failed to demonstrate the survival benefit of D2 plus 
PAND over D2 alone.37,38 Also, lymph node station 14v 
(along the superior mesenteric vein) has been excluded from 
D2, even for distal tumors, in the new treatment guidelines 
set forth by the Japanese Gastric Cancer Association 
(JGCA),39 which is consistent with the findings of retrospec-
tive study from our own institution in which 14v-positive 
gastric cancer demonstrated poor prognosis, similar to that 
of metastatic disease.40,41
Bursectomy is a procedure dissecting the peritoneal lin-
ing covering the pancreas and the anterior leaf of the trans-
verse mesocolon, and is commonly performed as a standard 
treatment with radical gastrectomy for advanced cancer in 
Eastern Asia.42 According to the Japanese Gastric Cancer 
Treatment Guidelines,39 bursectomy is recommended for 
tumors penetrating the serosa of the posterior gastric wall, 
in order to remove microscopic tumor deposits in the lesser 
sac. However, no evidence from large-scale randomized 
controlled trials has come forth to support that bursectomy 
improves survival by reducing peritoneal or local recur-
rence. The JCOG 1001 trial is currently ongoing to pro-
spectively compare the clinical benefit of bursectomy in pa-
tients with clinical T3 (SS) and T4a (SE) tumor.43
Minimally invasive management of EGC
Endoscopic mucosal resection (EMR) is a treatment option 
of EGC with an extremely low possibility of lymph node 
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In Japan, adjuvant S-1 therapy has become the standard 
treatment of choice for patients with AGC after D2 resec-
tions based on the positive results of the Adjuvant Chemo-
therapy Trial of S-1 for Gastric Cancer (ACTS-GC).56 One 
year after enrollment and randomization of 1,059 patients, 
the first interim analysis showed that both overall survival 
and relapse-free survival were significantly higher in the 
S-1 group, and the trial was discontinued following the rec-
ommendation of the monitoring committee. Subsequently, 
the updated data of 5-year outcomes reconfirmed the sur-
vival benefit of adjuvant S-1 therapy; the overall survival 
rates at 5-years in the S-1 group and in the surgery-only 
group were 71.7% and 61.1% (HR 0.669; 95% CI 0.540-
0.828), and the relapse-free survival rates in the S-1 and 
surgery-only group were 65.4% and 53.1% (HR 0.653; 
95% CI 0.537-0.793), respectively.57 Accordingly, new JGCA 
treatment guidelines39 recommend adjuvant S-1 chemother-
apy as a standard treatment for patients of stage II-III, ex-
cept for T1 andT3/N0, during the first year after R0 gastrec-
tomy with D2 lymphadenectomy.
Recently, interim analysis of international (Korea, China, 
and Taiwan), multicenter, randomized, phase III trials (CLAS-
SIC) was reported as an abstract,58 comparing capecitabine 
plus oxaliplatin (CapOX) adjuvant chemotherapy group 
with an observation group following D2 resections in a total 
of 1,035 patients with locally advanced cancer. After the me-
dian follow-up of 34.4 months, 3-year disease-free survival 
was significantly higher in the CapOX group (74% vs. 
60%; HR=0.56, 95% CI 0.44-0.72; p<0.0001), although a 
difference in overall survival has not yet been observed. 
Grade 3 or 4 adverse events occurred in 49% of patients in 
the CapOX group with serious toxicity reported in 7% of 
them, which was consistent with well-known safety pro-
files of CapOX. The final overall survival results of the 
CLASSIC trial assessing the clinical benefits of adjuvant 
chemotherapy following D2 resection are still awaited, al-
though the preplanned interim analysis met its primary end-
point of 3-year disease-free survival.
Based on the results of the two randomized trials (ACTS-
GC and CLASSIC), therefore, it is strongly suggested that 
5FU-derivative based chemotherapy in an adjuvant setting 
following D2 resections would invariably deliver the best 
current clinical benefits to the patients with resectable gas-
tric cancer.
Postoperative radiochemotherapy
With the positive results of the intergroup 0116 trial (South-
be considered in regards to minimizing unnecessary proce-
dures carrying morbidities and facilitating postoperative re-
covery, if it does not violate oncologic principles. There are 
a couple of simple methods for improving QoL in gastric 
cancer patients without having to perform additional proce-
dure or pay additional costs.
For example, the length of conventional midline incision 
for laparotomy can be shortened by approximately 10 cm 
without sacrificing a good surgical field. At our institution, 
a small upper midline incision above the umbilicus is made 
for radical gastrectomy with D2 lymphadenectomy in order 
to reduce surgical stress. Also, an electrosurgical device is 
able to replace the traditional clamp-and-tie technique in the 
trimming of the lesser and greater curvature of the stomach 
and is superior in reducing operation time and the number 
of intra-abdominal foreign body like suture materials in 
gastric cancer surgery, while remaining cost-effective.49 In 
order to avoid the placement of nasogastric tubes which 
cause significant patient discomfort, intraoperative needle 
decompression of the stomach and transverse colon is a 
simple and safe alternative method for achieving optimal 
gastrointestinal decompression for a good surgical field.50,51 
Also, an intra-abdominal drain should not be routinely placed 
during the operation, as a prospective randomized trial 
from our institution showed that the prophylactic use of in-
tra-abdominal drain does not offer any additional benefit to 
decrease surgical complications, including intraabdominal 
fluid collection or abscess, but rather increases morbidi-
ties.52 All of these efforts improve the QoL of gastric cancer 
patients and have cost-effectively led to lower postopera-
tive morbidity and shorter hospital stay.
Adjuvant chemotherapy
Although curative D2 resection is the standard treatment of 
operable gastric cancer, 40-60% of patients with locally ad-
vanced cancer experience recurrence after surgery.53,54 Adju-
vant chemotherapy, suspected to reduce this recurrence, had 
shown limited and inconsistent efficacy in previous trials. 
However, a recent large meta-analysis (GASTRIC group), 
in which 3,838 individual patients from 17 trials were evalu-
ated, reported a small but significant benefit of adjuvant che-
motherapy after curative resection of gastric cancer [hazard 
ratio (HR) 0.82; 95% confidence interval (CI) 0.76-0.90; 
p<0.001].55 The authors suggested that postoperative adju-
vant chemotherapy based on fluorouracil regimens was as-
sociated with a reduced risk of death in gastric cancer, com-
pared with surgery alone.
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benefit of neoadjuvant chemotherapy in addition to D2 re-
section remains unclear.
FUTURE STRATEGY FOR  
GASTRIC CANCER
Sentinel lymph node navigation and individualized 
resection
Radical gastrectomy with D2 lymphadenectomy is now 
universally accepted as the standard surgical treatment of 
AGC in specialized high-volume centers. This does not im-
ply, however, that extended resection is the only option for 
surgical management of gastric cancer regardless of stage. 
Individualized resection and lymphadenectomy along with 
accurate prediction of primary tumor status and regional 
lymph nodes prior to surgery are needed for the tailored 
management and better QoL of gastric cancer patients. 
Widely used in breast cancer and melanoma, sentinel 
lymph node (SN) biopsy could be utilized to determine the 
extent of lymph node dissection required in gastric cancer 
as well, and indeed, the efficacy of lymphatic basin dissec-
tion in EGC navigated by SN identification has been re-
cently studied in many centers. However, as methodologies 
vary widely in terms of SN identification, lymph node 
mapping, and intraoperative diagnosis of metastatic lymph 
nodes,62 the accuracy and validity of a standardized tech-
nique need to be established first prior to its clinical appli-
cation in the future.
Molecular biomarkers and targeted therapy
The prognosis of patients with AGC is still dismal even with 
marked advances in chemotherapeutic agents over the past 
decades. Moreover, treatment responses and prognosis are 
highly variable even within the same stage. Therefore, a 
thorough understanding of cancer biology is essential for 
better management of gastric cancer in the future. Cancer is 
basically a disease of genetics, and underlying molecular 
aberrations dictate the clinical behaviors of tumors, such as 
therapy resistance, recurrence, and metastasis, that eventu-
ally lead to death. Therefore, elucidation of underlying bio-
logical mechanisms will help identify potential diagnostic 
markers and more importantly therapeutic targets. The best 
studied molecular targets so far in gastric cancer include 
epidermal growth factor receptors (EGFR) as well as vas-
cular endothelial growth factor (VEGF) and its receptors.
EGFR overexpression has been observed in many tumors 
west Oncology Group 9008),30 adjuvant radiochemotherapy 
with limited (D0 or D1) lymphadenectomy has been fre-
quently used in the United States. Macdonald, et al. reported 
promising results of the adjuvant radiochemotherapy after 
surgery with curative intent in patients with adenocarcino-
ma of the stomach or gastroesophageal junction, demon-
strating the significant superiority of radiochemotherapy 
over surgery alone in terms of relapse free survival and over-
all survival.30,31
Nonetheless it is crucial to consider that more than 50% 
of patients in this trial underwent gastric resection without 
any lymph node dissection (D0), and the limited (D1) and 
extended (D2) lymphadenectomy were performed in only 
36% and 10% of cases, respectively. Therefore, most resec-
tions performed were insufficient and inadequate to achieve 
loco-regional control which was thereafter improved by ad-
juvant radiotherapy. In Korea and Japan, however, prophy-
lactic D2 lymphadenectomy achieves good loco-regional 
control with much lower morbidity and mortality than 
those of radiotherapy, and the benefit of adjuvant radioche-
motherapy following D2 resection has yet to be estab-
lished59 by ongoing randomized controlled trials in Europe 
and Korea.
Neoadjuvant therapy
Neoadjuvant chemotherapy has been frequently used for 
locally advanced gastric carcinoma in the United States and 
Western Europe, ever since the Medical Research Council 
Adjuvant Gastric Infusional Chemotherapy trial (MAGIC 
trial) reported their first positive results. The MAGIC trial 
in patients with gastric and gastroesophageal junction can-
cer demonstrated that the perioperative chemotherapy group, 
compared to the surgery alone group, showed significant 
improvement in resectability, as well as disease-free and 
overall survival.60 Likewise, a recent phase III randomized 
trial by the Fédération Nationale des Centres de Luttecontre 
le Cancer and the Fédération Francophone de Cancérologie 
Digestive in 28 French centers also reported positive results 
similar to the MAGIC trial.61
Despite their promising results, however, limitations pre-
vent the application thereof as a standard treatment of gas-
tric cancer, because both trials included high proportions of 
distal esophagus and gastroesophageal junction tumors, and 
less than 50% of the patients completed postoperative che-
motherapy as initially planned, and most importantly there 
were no standard preoperative staging systems. Moreover, 
without hazard ratio analysis on the extent of surgery, the 
Joong Ho Lee, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 2   March 2012254
ological manifestations of gastric cancer between the two 
topographic regions are different and this distinction should 
be taken into account when global multicenter trials are 
planned. Actually, this geographical difference was con-
firmed in the subgroup analysis of the recently published 
the Avastin in Gastric Cancer (AVAGAST) trial.66
Bevacizumab (Avastin®) is a humanized monoclonal an-
tibody against VEGF, which is an endothelial cell-specific 
mitogen and the most potent driver of angiogenesis in tu-
morigenesis as it increases microvascular permeability. The 
inhibition of VEGF by bevacizumab has had a positive im-
pact on patient outcomes in several malignancies including 
colorectal, lung, and renal cell carcinoma, as well as recur-
rent glioblastoma.67 In gastroesophageal cancer, VEGF is 
overexpressed by up to 60%, a much higher rate than HER-
2/neu, and its overexpression correlates with advanced stage, 
higher risk of recurrence, and poor survival.68
AVAGAST was a multinational, randomized, double-
blind, placebo-controlled phase III clinical trial which set 
out to evaluate the anti-angiogenic agent bevacizumab 
combined with chemotherapy (capecitabine plus cisplatin) 
as a first-line therapy in patients with unresectable far ad-
vanced gastric carcinoma.66 Although AVAGAST did not 
reach its primary endpoint with no significant difference in 
overall survival (12.1 months in bevacizumab plus chemo-
therapy vs. 10.1 months in placebo plus chemotherapy; HR 
0.87; p=0.1002), both progression-free survival (6.7 vs. 5.3 
months; HR 0.80; p=0.0037) and overall response rate 
(46.0% vs. 37.4%; p= 0.0315) were improved significantly 
in the bevacizumab-arm. It must be noted that preplanned 
subgroup analysis demonstrated regional differences in the 
efficacy of the bevacizumab, as patients enrolled only in 
Pan-America demonstrated a significant survival benefit 
with the addition of bevacizumab (median survival 11.5 vs. 
6.8 months; HR 0.63; 95% CI 0.43 to 0.94). It is not clear 
whether the discrepancy came from genetic differences in 
ethnicity or from differences in treatment patterns such as 
palliative resection and second-line chemotherapy. Regard-
less, it surely provides a direction to investigate further in 
future research and clinical trials.
CONCLUDING REMARKS
　
The overall survival of gastric cancer has gradually improved 
over the past few decades with advances in surgical tech-
niques, the evolution of multimodality treatments, and ear-
including gastric cancer and is generally thought to corre-
late with increased tumor invasion, more poorly differenti-
ated histology, and a worse prognosis.63 Trastuzumab (Her-
ceptin®) is a humanized monoclonal antibody that interferes 
with human EGFR type 2 (HER-2/neu, ErbB-2). The HER 
family proteins regulate cell growth, survival, adhesion, mi-
gration, and differentiation, which are amplified or weak-
ened in cancer cells.64
The trastuzumab for Gastric Cancer (ToGA) trial, a piv-
otal randomized clinical trial of patients with HER-2 posi-
tive advanced, mostly metastatic, gastric cancer, proved the 
efficacy of trastuzumab in combination with chemothera-
py.65 The median overall survival was significantly pro-
longed in the trastuzumab-containing arm (13.8 vs. 11.1 
months; HR 0.74; p=0.0046) without unexpected toxicity 
including cardiac events. Furthermore, the survival benefit 
was most pronounced in the subgroup of high HER-2/neu 
protein overexpression (median overall survival of 16 
months). Indeed, recent success in the ToGA trial suggested 
that other biological pathways could be utilized to develop 
new therapeutic agents if we appropriately identify patients 
with target pathways that drive tumor behavior. The impli-
cations of the ToGA trial are tremendous in that the results 
provide a couple of crucial points that should be considered 
when planning and conducting biomarker based targeted 
therapy.
First of all, companion diagnostics are essential to suc-
cessfully identifying subgroups of patients who will benefit 
from a given targeted drug. Patients with high levels of HER-
2 expression upon immunohistochemistry staining showed 
clinical benefits with trastuzumab. Therefore, it should be 
noted that robust clinical molecular testing is paramount for 
successful targeted therapeutics development. Secondly, the 
target should be dominant in cancer biology, and its modu-
lation should alter the clinical behavior of cancer. The inhi-
bition of HER-2, which is associated with poor prognosis, 
with trastuzumab improved clinical outcomes, prolonging 
survival rates. Lastly, HER-2 and trastuzumab exemplify 
the type of diagnostic markers or targetable biomarkers fun-
damental to the cancer biological therapy. HER-2 itself is a 
predictive marker and simultaneously a therapeutic target; 
thus, simple HER-2 testing is able to generate critical infor-
mation to aid clinical decision making in order to treat pa-
tients properly.
Furthermore, understanding genetic and molecular differ-
ences between Asian and Western gastric cancer would help 
establish refined treatment strategies. The clinical and path-
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specific to gastric cancer is warranted for use not only as 
prognostic indicators but also as therapeutic targets.
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